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Abstract
Background: TRIM5α, which is expressed in most primates and the related TRIMCyp, which has
been found in one of the New World monkey species, are antiviral proteins of the TRIM5 family
that are able to intercept incoming retroviruses early after their entry into cells. The mechanism
of action has been partially elucidated for TRIM5α, which seems to promote premature
decapsidation of the restricted retroviruses. In addition, through its N-terminal RING domain,
TRIM5α may sensitize retroviruses to proteasome-mediated degradation. TRIM5α-mediated
restriction requires a physical interaction with the capsid protein of targeted retroviruses. It is
unclear whether other cellular proteins are involved in the inhibition mediated by TRIM5α and
TRIMCyp. A previous report suggested that the inhibition of HIV-1 by the rhesus macaque
orthologue of TRIM5α was inefficient in the D17a canine cell line, suggesting that the cellular
environment was important for the restriction mechanism. Here we investigated further the
behavior of TRIM5α and TRIMCyp in the D17 cells.
Results: We found that the various TRIM5α orthologues studied (human, rhesus macaque, African
green monkey) as well as TRIMCyp had poor antiviral activity in the D17 cells, despite seemingly
normal expression levels and subcellular distribution. Restriction of both HIV-1 and the distantly
related N-tropic murine leukemia virus (N-MLV) was low in D17 cells. Both TRIM5αrh and
TRIMCyp promoted early HIV-1 decapsidation in murine cells, but weak levels of restriction in D17
cells correlated with the absence of accelerated decapsidation in these cells and also correlated
with normal levels of cDNA synthesis. Fv1, a murine restriction factor structurally unrelated to
TRIM5α, was fully functional in D17 cells, showing that the loss of activity was specific to TRIM5α/
TRIMCyp.
Conclusion: We show that D17 cells provide a poor environment for the inhibition of retroviral
replication by proteins of the TRIM5 family. Because both TRIM5α and TRIMCyp are poorly active
in these cells, despite having quite different viral target recognition domains, we conclude that a
step either upstream or downstream of target recognition is impaired. We speculate that an
unknown factor required for TRIM5α and TRIMCyp activity is missing or inadequately expressed
in D17 cells.
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Background
TRIM5α is a primate protein expressed in the cytoplasm of
many cell types that is able to inhibit ("restrict") the rep-
lication of selected retroviruses [1-3]. Individual TRIM5α
alleles are able to restrict a few or many retroviruses
(although never all of them). The specificity of the restric-
tion, i.e. the viral targets for each particular TRIM5α allele,
is species-dependent more than it is cell type-dependent.
The specific recognition of viral targets is determined by
the SPRY/B30.2 region at the C-terminus of TRIM5α [4-9].
On the virus side, capsid (CA) proteins seem to be the
only determinant of sensitivity to TRIM5α [10-12], and a
physical interaction takes place between TRIM5α and cap-
sid, as evidenced by pull-down assays [13,14]. It is worth
noting, however, that the interaction has not yet been
documented using purified TRIM5α, and thus it is possi-
ble that other cellular factors are relevant to this step.
TRIM5α forms trimers and possibly multimers of higher
orders of complexity [15,16]. TRIM5α multimerization is
linked to its restriction activity [17]. In addition, TRIM5α
targets multimers of properly maturated and assembled
retroviral CA constituting the capsid core of incoming
viral particles [18,19]. Thus, the initial TRIM5α-retrovirus
interaction might involve the assembly of a multimer of
TRIM5α around the capsid core of incoming retroviruses
very early after entry.
Following this initial interaction, replication of the
restricted retrovirus can be impaired in several ways. First,
TRIM5αrh  and TRIM5αhu  seem to promote premature
decapsidation of HIV-1 and N-tropic murine leukemia
virus (N-MLV), respectively [14,20]. More specifically,
TRIM5α causes post-entry disappearance of CA in its par-
ticulate form, which is assumed to belong to not-yet-dis-
assembled viruses. Second, replication is inhibited by a
mechanism involving the proteasome. This is evidenced
by the partial rescue of retroviral replication from TRIM5α
restriction in the presence of the proteasome inhibitor
MG132 [21,22]. In addition, the ubiquitin ligase activity
associated with the RING domain of TRIM5α is important
for full restriction activity [3]. It has also been proposed
recently that TRIM5αrh might promote the degradation of
HIV-1 CA through a non-proteasomal, non-lysosomal
pathway [23]. Thirdly, TRIM5α interferes with the nuclear
transport of retroviral pre-integration complexes [21,22].
TRIM5α from the squirrel monkey seems to restrict the
mac251 strain of simian immunodeficiency virus
(SIVmac251) mostly, if not only, by inhibiting this
nuclear transport step [24].
Interestingly, a recent report pointed to late steps (i.e.
assembly and release) of retroviral replication as possibly
targeted by TRIM5α, although the molecular basis for late-
stage restriction specificity is distinct from that of early
stages [25].
In the owl monkey, a New World species, the SPRY/B30.2
domain of TRIM5α is replaced by the full coding sequence
of the highly conserved, ubiquitously expressed peptidyl-
prolyl isomerase Cyclophilin A (CypA), yielding a protein
called TRIMCyp or TRIM5-CypA [26,27]. TRIMCyp inhib-
its HIV-1, the African green monkey strain of SIV
(SIVAGM), feline immunodeficiency virus (FIV) and
equine infectious anemia virus (EIAV) [28-30]. CypA was
isolated fifteen years ago as a cellular protein interacting
with HIV-1 CA [31] and TRIMCyp binds CA through its
CypA domain [27,28]. CypA-CA interaction and TRIM-
Cyp-mediated restriction are abrogated in the presence of
cyclosporine (CsA), a drug that targets the same structural
motif in CypA to which CA binds [27,32]. Like TRIM5αrh,
TRIMCyp causes an early block to HIV-1 replication, pre-
venting the accumulation of retroviral cDNA in the
infected cells [16,28,33]. Prior to the present work, how-
ever, it was not known whether TRIMCyp promoted HIV-
1 premature decapsidation.
Are other cellular factors important for the restriction
mediated by TRIM5α? Efficient inhibition of HIV-1 by
TRIM5α in several Old World monkey cell lines requires
the presence of CypA, as seen by gene knock-down
[34,35]. The proposed model [34] is that CypA catalyzes
the cis-trans isomerization of HIV-1 CA at proline 90 [36],
thus turning it into a target for some simian TRIM5α
orthologues. However, the impact of CypA on the restric-
tion of HIV-1 is much less significant when TRIM5α is
over-expressed in non-primate cells [34,35,37]. It is not
clear whether other cellular proteins are important in the
steps leading to the initial viral recognition step. Down-
stream of this TRIM5α-target interaction, it is expected
that cellular proteins take part in the targeting of restricted
viruses to proteasome-dependent degradation, although
the exact mechanism has not been elucidated yet.
Whether cellular proteins other than TRIM5α are also
required for CA premature decapsidation and the inhibi-
tion of nuclear transport is totally unknown.
The restriction phenotype stemming from TRIM5α and
TRIMCyp activity is retained upon expression of these
proteins in non-primate cells such as murine and feline
cells, suggesting that if cellular factors other than TRIM5α
are required, they must be widely conserved among mam-
mals. However, the Poeschla group recently reported that
restriction of HIV-1 by the rhesus macaque TRIM5α
orthologue was inefficient in D17 cells, a canine osteosa-
rcoma cell line [38]. As a first step toward the isolation of
additional factors involved in the restriction by TRIM5α,
we decided to characterize further the restriction pheno-
type in the D17 cells.Retrovirology 2007, 4:68 http://www.retrovirology.com/content/4/1/68
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Results
We transduced C-terminal FLAG versions of TRIM5α (rhe-
sus macaque, African green monkey, and human) and
TRIMCyp (owl monkey) into mus dunni tail fibroblasts
(MDTF) and D17 cells. Cell lines homogeneously express-
ing each TRIM5 orthologue were obtained following
puromycin treatment. Steady-state levels of TRIM5 expres-
sion were similar in MDTF and D17 cells, as judged by
western blotting (Fig. 1A). Curiously, we could not detect
the human TRIM5α orthologue in either cell line. How-
ever, N-tropic murine leukemia virus (N-MLV) was
restricted in the MDTF cells expressing TRIM5αhu  as
expected (Fig. 2), and sequencing analysis of pMIP-
TRIM5αhu confirmed the presence of the FLAG tag. Thus,
it appears that TRIM5αhu-FLAG has constitutively small
steady-state expression levels, an observation previously
made by others [39]. We used immunofluorescence (IF)
microscopy to analyze the subcellular distribution of
TRIM5αrh and TRIMCyp in MDTF cells and in D17 cells
(Fig. 1B). Both proteins were cytoplasmic and formed
bodies in the two cell types. Thus, expression and locali-
zation of TRIM5α and TRIMCyp were seemingly normal
in the D17 cells.
We then challenged the cell lines generated with N-MLV
and B-MLV vectors expressing GFP. Upon infection with
multiple virus doses, we found as expected that N-MLV
was 10- to 12-fold less infectious in the MDTF cells
expressing the human or African green monkey ortho-
logues of TRIM5α, compared with the control cells (Fig.
2A). In the D17 cells, however, the magnitude of restric-
tion by TRIM5αhu or TRIM5αAGM was only to 2- to 3-fold.
As expected, B-tropic MLV replication was not affected by
any of the TRIM5α orthologues. In an independent exper-
iment, we infected all the MDTF and D17 cell lines gener-
ated with N-MLVGFP and B-MLVGFP at a single virus dose.
TRIM5αAGM and TRIM5αrh each inhibited N-MLV infec-
tion by about 100-fold in the MDTF cells, and TRIM5αhu
had an even greater inhibitory effect (Fig. 2B). In contrast,
restriction in the D17 cells was much smaller (about 10-
fold) (Fig. 2B). As expected, N-MLV was not inhibited by
TRIMCyp and B-MLV was not inhibited by either TRIM5α
or TRIMCyp.
We next investigated the levels of restriction of HIV-1 in
the various cell lines. Upon challenge at multiple virus
doses, we found HIV-1GFP to be strongly inhibited (about
100-fold; Fig. 3A) in the MDTF cells expressing either
TRIM5αrh or TRIMCyp, as expected. In contrast, the level
of restriction by these TRIM5 proteins was much smaller
in the D17 cells (about 3-fold). In another experiment, we
infected MDTF, HeLa, and D17 cells expressing either
TRIM5αrh or TRIMCyp with HIV-1GFP at a fixed virus dose.
In these conditions, we found that TRIM5αrh and TRIM-
Cyp caused a ≈ 100-fold decrease in infection by HIV-1GFP
in MDTF or HeLa cells. In D17 cells, however, the decrease
in infectivity was of only 5-fold. Thus, restriction of both
N-MLV and HIV-1 by either TRIM5α or TRIMCyp was
inefficient in the D17 cells.
Restriction of lentiviruses by TRIMCyp is abrogated in the
presence of cyclosporine A (CsA), a competitive inhibitor
of cyclophilins. We reasoned that if TRIMCyp inhibited
HIV-1 more efficiently in MDTF cells compared to the
D17 cells, then the level of enhancement of HIV-1 infec-
tion by CsA should also be greater. Thus, we infected
MDTF and D17 cells with HIV-1GFP at a multiplicity of
infection (MOI) of 1 to 3% infected cells and in the pres-
ence of increasing CsA concentrations. In MDTF-TRIM-
Cyp cells, CsA enhanced HIV-1 infection by 60-fold (Fig.
4A), consistent with the high level of restriction in these
cells. In contrast, CsA-mediated enhancement of HIV-1
replication in D17-TRIMCyp cells was much smaller (5-
fold). We performed an additional experiment using an
optimal CsA concentration (6 µM) and multiple MOIs
(Fig. 4B). CsA completely abrogated TRIMCyp-mediated
restriction in both MDTF and D17 cells, but the magni-
tude of CsA-mediated enhancement of HIV-1 replication
was about 20-fold greater in MDTF-TRIMCyp cells com-
pared to D17-TRIMCyp.
Restriction of both HIV-1 and N-MLV by TRIM5α has
been associated with a loss of particulate CA [14,20]. Post-
entry particulate CA is believed to be a marker of viruses
not yet disassembled, as disassembly of the retroviral core
leads to increased CA solubility. Using a 50% sucrose
cushion, we separated particulate CA from soluble CA fol-
lowing HIV-1 virus-like particles (VLPs) infection of
MDTF and D17 cells expressing TRIM5αrh or TRIMCyp.
Examination of CA in whole lysates and in soluble "super-
natant" fractions revealed a larger amount of CA in D17
cells compared with the MDTF cells (Fig. 5). Presumably,
this could be due to more efficient virus entry in the D17
cells. Uncleaved Gag proteins and Gag maturation inter-
mediates were detected in whole lysates and in some pel-
lets, but this observation did not fit any obvious trend and
had low reproducibility (not shown). As expected, there
was a decrease (6-fold) in particulate CA in the MDTF-
TRIM5αrh cells, compared with the control MDTF cells.
The same phenotype was observed in the MDTF-TRIMCyp
cells, indicating that TRIM5α and TRIMCyp, despite dif-
ferences in the CA-binding region, inhibit retroviral repli-
cation through similar mechanisms. We also noted that
the decrease in particulate CA was not accompanied by an
obvious increase in soluble CA (Fig. 5 and Fig. 6). In the
D17 cells, TRIM5αrh and TRIMCyp both decreased the lev-
els of particulate HIV-1 CA compared with the control
cells, but the magnitude of the effect was significantly
lesser than in the MDTF cells.Retrovirology 2007, 4:68 http://www.retrovirology.com/content/4/1/68
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Expression and subcellular distribution Figure 1
Expression and subcellular distribution. A, FLAG-tagged TRIM5α (rhesus, human, or African green monkey orthologues) 
and TRIMCyp were stably expressed in MDTF and in D17 cells, and expression was assessed by western blotting with antibod-
ies directed against FLAG (top) or actin (bottom). The percentage of transduced cells was roughly similar for all cell lines cre-
ated, as judged by the percentage of puromycin-resistant cells (not shown). The presence of the FLAG tag in TRIM5αhu was 
confirmed by sequencing of the plasmid DNA. B, MDTF or D17 cells expressing TRIM5αrh or TRIMCyp were fixed and stained 
using an antibody against FLAG and counterstained with Hoechst33342 to reveal DNA.
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Restriction of N-MLV Figure 2
Restriction of N-MLV. A, MDTF or D17 cells expressing TRIM5αhu, TRIM5αAGM, or control cells were infected with multi-
ple dilutions of N-MLV and B-MLV vectors expressing GFP. The percentage of infected cells was determined by flow cytome-
try. B, MDTF or D17 cells expressing various orthologues of TRIM5α, or expressing TRIMCyp, were infected with GFP-
expressing N-MLV or B-MLV vectors. The virus dose used in each cell type was first adjusted so that 5–10% of control cells 
would be infected and the same volume of virus preparation was then used to infect the various TRIM5-expressing cell lines 
from that cell type. The percentage of infected cells was determined 2 days later by flow cytometry, and results are shown as 
% of the values obtained for the control cells. The experiment was carried out in triplicates, and standard deviations are 
shown.
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Both TRIMCyp-mediated restriction of HIV-1 and
enhancement of HIV-1 replication by CsA are more effi-
cient in the MDTF cells compared with the D17 cells (Fig.
3 and 4). Thus, we examined the effect of CsA on the levels
of particulate CA in MDTF-TRIMCyp and D17-TRIMCyp
cells (Fig. 6). Like before, the decrease in particulate CA
caused by TRIMCyp was more acute in the MDTF cells
compared with the D17 cells (5-fold versus 1.6-fold). In
addition, CsA restored wild-type levels of particulate CA
Enhancement of HIV-1 infection in cells expressing TRIMCyp  by cyclosporine Figure 4
Enhancement of HIV-1 infection in cells expressing 
TRIMCyp by cyclosporine. A, MDTF or D17 cells, 
expressing TRIMCyp or not (control cells), were infected 
with HIV-1GFP. The virus dose was adjusted so that 1% to 3% 
of cells would be infected in the absence of cyclosporine for 
each cell line, and the infections were done in the presence 
of various cyclosporine concentrations. The percentage of 
infected cells was determined 2 days later by flow cytometry. 
B, as above, except that CsA concentration was constant (6 
µM) and cells were infected with multiple doses of HIV-1GFP.
A
B
Restriction of HIV-1 Figure 3
Restriction of HIV-1. A, MDTF or D17 cells expressing 
TRIM5αrh, TRIMCyp, or control cells were infected with 
multiple dilutions of HIV-1GFP, an HIV-1 vector expressing 
GFP. The percentage of infected cells was determined by 
flow cytometry. B, MDTF, HeLa or D17 cells expressing 
TRIM5αrh or TRIMCyp, and control cells were infected with 
HIV-1GFP. The virus dose used in each cell type was first 
adjusted so that 5–10% of control cells would be infected and 
the same volume of virus preparation was then used to infect 
the various TRIM5-expressing cell lines from that cell type. 
The percentage of infected cells was determined 2 days later 
by flow cytometry, and results are shown as % of the values 
obtained for the control cells. The experiment was carried 
out in triplicates, and standard deviations are shown.
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in both cell types, although, as expected, the magnitude of
this effect was greater in the MDTF cells.
TRIM5αrh and TRIMCyp both inhibit HIV-1 cDNA accu-
mulation in their cognate species and this phenotype is
maintained upon expression in non-primate cells. We
used standard PCR and real-time PCR to analyze the levels
of HIV-1 cDNA after a 12-hours HIV-1GFP infection of
MDTF and D17 cells expressing TRIM5αrh or TRIMCyp
(Fig. 7). The oligodeoxynucleotide pair used amplified a
sequence within the GFP cDNA. Compared with control
cells, both TRIM5αrh  and TRIMCyp caused a sharp
decrease in the accumulation of viral cDNA in the MDTF
cells. As expected, CsA rescued HIV-1 cDNA synthesis to
near-normal levels. On the other hand, TRIM5αrh and
TRIMCyp caused little or no decrease in HIV-1 cDNA lev-
els in D17 cells and CsA had little or no effect on the levels
of cDNA in the D17-TRIMCyp cells (Fig. 7).
Fv1, the murine retroviral restriction factor described and
cloned decades ago [40,41], also targets incoming retrovi-
ruses at an early post-entry step. Although fv1 is related to
the  gag  region of murine endogenous retroviruses and
bears no immediate similarities to TRIM5, residues in
MLV CA proteins are determinants in both Fv1 and
TRIM5α-mediated restrictions [42]. Consequently, Fv1
and TRIM5α compete with one another for the binding to
putative restriction targets when co-expressed in the same
cells [43]. We transduced the N-MLV-targeting Fv1b in
both D17 and MDTF cells and monitored the effect of its
expression on the replication of N-MLV and, as a control,
B-MLV (Fig. 8). As expected, Fv1b strongly inhibited N-
MLV in the MDTF cells (more than 100-fold) while it had
little effect on B-MLV. Restriction of N-MLV in D17-Fv1b
cells was efficient, albeit slightly less so than in MDTF-
Fv1b cells. Thus, loss of restriction activity in D17 cells
seems to be specific to TRIM5α.
Discussion
The mechanism by which TRIM5α and TRIMCyp inter-
cept and inhibit incoming retroviruses is incompletely
understood. TRIM5α is able to trimerize in cells, and it is
probably in this form (or as a multimer of higher com-
plexity) that it recognizes its viral target [15,17]. This ini-
tial interaction is followed by the disappearance of
particulate CA but not soluble CA. The loss of particulate
Fate-of-capsid assay Figure 6
Fate-of-capsid assay. MDTF and D17 cells expressing 
TRIMCyp, and control cells were infected with HIV-1 VLPs 
as in Fig. 5. The cells expressing TRIMCyp were infected in 
the presence or not of cyclosporine (5 µM). CA was 
detected in post-sedimentation pellets and supernatants. Pel-
let CA was quantitated as in Fig. 5.
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Fate-of-capsid assay Figure 5
Fate-of-capsid assay. MDTF or D17 cells expressing 
TRIM5αrh or TRIMCyp and control cells were infected with 
HIV-1 VLPs for 4 hours, then cells were allowed to grow for 
2 more hours in a virus-free medium. Following the infection, 
cells were submitted to hypotonic lysis and the protein sus-
pension was sedimented through a 50% sucrose gradient. 
HIV-1 CA was detected by western blotting of whole lysates, 
post-sedimentation pellets and supernatants (materials that 
did not enter the sucrose cushion). The mature CA (24 kDa) 
band was quantitated for the blot showing the pellet fractions 
and quantitation data are shown expressed as relative values.
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CA has been attributed to an acceleration of viral uncoat-
ing in restrictive conditions [14,20]. However, as observed
here and by others [14], the decrease in particulate HIV-1
CA in restrictive conditions is not necessarily accompa-
nied by an increase in soluble CA. Thus, it remains possi-
ble that incoming retroviral cores are not disassembled
faster under TRIM5α/TRIMCyp restriction but instead are
specifically targeted to a degradation pathway. Accord-
ingly, pharmacological approaches have revealed a role
for the proteasome in the restriction mediated by TRIM5α
[21,22]. Of course, the two models are not mutually
exclusive, as proteasome-mediated degradation might
well follow premature decapsidation.
We find retroviral restrictions mediated by either TRIM5α
or TRIMCyp (but not Fv1) to be poorly efficient in the
canine cells D17. These results confirm and extend previ-
ous findings by Saez and colleagues [38]. The restriction
defect did not appear to be caused by poor expression or
mislocalization of TRIM5α or TRIMCyp. Consistent with
the HIV-1GFP transduction data, TRIM5α and TRIMCyp
had little effect on the accumulation of HIV-1 cDNA in
D17 cells. In addition, TRIM5α and TRIMCyp induced the
disappearance of HIV-1 particulate CA at relatively low
rates in D17 cells, compared with the MDTF cells. There-
fore, D17 cells provided a poor environment for the
restriction. We hypothesize that a cellular factor impor-
tant for the activity of TRIM5α and TRIMCyp is not func-
tional or is expressed at low levels in these cells. The
missing factor might be important for TRIM5 multimeri-
zation or for its interaction with the proteasome. Con-
versely, a dominant negative factor might be expressed in
the D17 cells. That both N-MLV and HIV-1 were less
restricted in D17 cells implies that CypA is not relevant to
the observed phenotype. Reciprocally, it is unlikely that
the SPRY/B30.2 domain of TRIM5α is relevant to its loss
Restriction by Fv1 Figure 8
Restriction by Fv1. MDTF or D17 cells, expressing Fv1b or 
not (control cells), were infected with multiple dilutions of 
N-MLV and B-MLV vectors expressing GFP. The percentage 
of infected cells was determined by flow cytometry 2 days 
later.
Retroviral cDNA synthesis Figure 7
Retroviral cDNA synthesis. MDTF or D17 cells express-
ing the indicated TRIM5 orthologues were infected for 12 
hours with HIV-1GFP at a MOI yielding about 20% infected 
cells for the control cells. In addition, infection of cells 
expressing TRIMCyp was carried out in the presence or 
absence of 5 µM cyclosporine, and infection of control cells 
was done in the presence or absence of the reverse tran-
scriptase inhibitor nevirapine (80 µM). Top panel, total cellu-
lar DNAs were extracted and an aliquot of each DNA 
sample was subjected to a 30-cycle PCR amplification using 
ODNs annealing to GFP sequences. PCR products were sep-
arated on an agarose gel and revealed with ethidium bro-
mide. Bottom panel, as above but HIV-1GFP-specific DNAs 
were quantitated by real-time PCR, using dilutions of a plas-
mid containing the GFP sequence as a standard.
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of function in the D17 cells, since a similar effect was
observed with TRIMCyp.
Conclusion
The canine D17 cells offer a cellular context that is unfa-
vorable to the restriction mechanism mediated by
TRIM5α and TRIMCyp. This cell line may thus represent a
unique opportunity to isolate and characterize cellular
genes regulating retroviral restrictions.
Methods
Plasmid DNAs
pMIP-TRIM5αrh-FLAG, pMIP-TRIM5αAGM-FLAG, pMIP-
TRIM5αhu-FLAG, and pMIP-TRIMCyp-FLAG express C-
terminal FLAG tagged versions of cDNAs amplified
respectively from rhesus macaque FRhK4 cells, African
green monkey Vero cells, human TE671 cells, or owl mon-
key OMK cells, and were generous gifts from Jeremy
Luban [39]. pCLNCX-Fv1b [43], which encodes both Fv1b
and the red fluorescent protein (RFP), was a kind gift of
Greg Towers (University College, London). pMD-G,
p∆R8.9, pTRIP-CMV-GFP, pCL-Eco, pCIG3N, pCIG3B
and pCNCG have all been extensively described before
[44-49].
Cells and virus production
Human embryonic kidney 293T, human cervical epithe-
lial carcinoma cells HeLa, mus dunni tail fibroblasts
(MDTF; a gift from Jeremy Luban) and canine osteosar-
coma D17 cells (a kind gift from Monica Roth) were all
grown in DMEM medium supplemented with 10% fetal
bovine serum and antibiotics. All viruses used in this
study were produced through transient transfection of
293T cells using polyethylenimine. For that, a mixture of
the appropriate DNAs diluted in 1 ml of DMEM without
serum or antibiotics was mixed with 45 µl of a 1 mg/ml
solution of polyethylenimine (Polysciences). This trans-
fection mix was then added to 70% confluent 293T cells
in a 10-cm tissue culture dish. The next day, cells were
PBS-washed once and put back in culture in fresh
medium. 2 days after transfection, virus-containing super-
natants were collected, clarified by low-speed centrifuga-
tion and stored in 1-ml aliquots at -80°C.
To produce the CLNCX and MIP vectors used to transduce
fv1b and the various TRIM5 alleles, the transfection mix
included 10 µg of pCL-Eco, 5 µg of pMD-G, and 10 µg of
the appropriate pMIP or pCLNCX construct. To produce
the N-MLVGFP and B-MLVGFP vectors, the transfection mix
included 10 µg of pCIG3 N or B, 5 µg of pMD-G, and 10
µg of pCNCG. To produce the HIV-1GFP vector, cells were
transfected with 10 µg of p∆R8.9, 5 µg of pMD-G, and 10
µg of pTRIP-CMV-GFP.
TRIM5-expressing cell lines
HeLa and D17 cells were plated at 300,000 cells per well
and MDTF cells were plated at 140,000 cells per well in 6-
well plates. The next day, supernatants were aspirated and
replaced with MIP-TRIM5α or MIP-TRIMCyp vector prep-
arations (2 ml per well). 2 days later, cells were placed in
medium containing 1 µg/ml (HeLa, D17) or 3 µg/ml
(MDTF) of puromycin (EMD Biosciences). These puromy-
cin concentrations were determined to kill all sensitive
cells after one or two days of treatment. Puromycin selec-
tion was allowed to proceed for 4 days, and then again
periodically during the course of this work. Expression of
the transduced TRIM5 cDNAs was analyzed by western
blotting, using antibodies directed against the FLAG
epitope (mouse monoclonal; Sigma) or actin (goat poly-
clonal; Santa Cruz).
Viral challenges
Cells were plated at 25,000 cells (HeLa, D17) or 10,000
cells (MDTF) in 0.4 ml per well of 24-well plates. Cells
were infected the next day with HIV-1GFP, N-MLVGFP, or B-
MLVGFP vectors. When CsA (Sigma) or nevirapine were
used, they were added 15 min prior to the virus. Cell
supernatants were replaced with fresh medium without
drugs 16 h after infection. 2 days after infection, cells were
trypsinized and fixed in 2% formaldehyde-PBS. Flow
cytometry was done on a FC500 MPL instrument (Beck-
man Coulter) using the CXP software for analysis. Intact
cells were identified based on light scatter profiles, and
only those cells were included in the analysis. Ten thou-
sand cells per sample were processed, and cells positive
for GFP expression were gated and counted as a percent-
age of total intact cells. Cells expressing Fv1b and RFP were
first gated for RFP expression and infected cells were com-
puted as % of cells expressing both RFP and GFP among
all RFP-positive cells. False-positive results were insignifi-
cant, as shown by controls corresponding to uninfected
cells (not shown).
IF microscopy
Cells were plated at 24,000 (MDTF) or 50,000 (D17) on
LabTek II four-chamber slides (LabTek). The next day,
cells were washed with PBS, fixed for 30 min in 4% for-
maldehyde-PBS, washed three times in PBS and permea-
bilized with 0.1% Triton X-100 for 2 min on ice. Cells
were then washed again with PBS and treated with 50 mM
NH4Cl (in PBS) for 10 min at RT. Then, cells were washed
3 times in PBS and treated with 10% normal goat serum
(Vector laboratories) for 30 min at RT. This saturation step
was followed by incubation with an antibody against
FLAG (M2 mouse monoclonal; Sigma) at a 1:400 dilution
in PBS with 10% normal goat serum. Fluorescent staining
was done using an Alexa488-conjugated goat anti-mouse
antibody (Molecular Probes) at a 1:500 dilution. Cells
were washed 4 times in PBS before mounting in Vectash-Retrovirology 2007, 4:68 http://www.retrovirology.com/content/4/1/68
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ield (Vector Laboratories). Hoechst33342 (0.8 µg/ml;
Molecular Probes) was added along with the penultimate
PBS wash to reveal DNA. Pictures were generated using a
Olympus BX-60 microscope with the Image-Pro Express
software.
Fate-of-capsid assay
The protocol used was adapted from Stremlau et al [14].
Cells were plated at 80% confluence in 10-cm culture
dishes. 12 hours later, they were layered with 8 ml of HIV-
1 VLPs, which is a high MOI (equivalent to 50–80%
infected control cells by HIV-1GFP). VLP infections were
performed in the presence or absence of nevirapine (80
µM) or CsA (5 µM). 4 hours later, supernatants were
replaced with fresh media containing the appropriate
drugs and the cells were put back in culture for an addi-
tional 2 hours. Cells were then lysed in 1.5 ml of a hypo-
tonic lysis buffer (100 µM Tris-Cl pH8.0, 0.4 mM KCl, 2
µM EDTA) containing a protease inhibitor mix (Sigma).
After Dounce homogenization (15 strokes) and clarifica-
tion by low-speed centrifugation, 50 µl of the lysate were
saved ("whole lysate"), and 1 ml was layered on top of a
50% sucrose cushion prepared in PBS. Particulate CA was
sedimented by ultracentrifugation using a Beckman
SW41Ti rotor. The centrifugation was carried in Beckman
Ultraclear tubes for 2 hours at 32,000 rpm and at 4°C.
Following this step, 200 µl of the supernatants were care-
fully transferred to a fresh tube and lysed in SDS sample
buffer. Remaining supernatant and sucrose cushions were
discarded by carefully inverting the tubes, and pellets were
resuspended in 50 µl of SDS sample buffer. Equal vol-
umes of whole cell lysate, supernatant, and pellet frac-
tions were processed for western blotting using a anti-CA
mouse monoclonal antibody (clone 183; a gift of Jeremy
Luban)
Monitoring HIV-1 cDNA synthesis
50,000 cells (D17) or 20,000 cells (MDTF) were plated in
0.4 ml per well in 24-well plates. 12 hours later, cells were
infected with 10 µl HIV-1GFP that had been treated with
DNase I (NEB; 23 U/ml of virus preparation) for 10 min
at 25°C. Cells were washed with PBS and trypsinized after
12 hours of infection. Total cellular DNA was extracted
using the DNeasy kit (Qiagen) and digested for one hour
at 37°C with Dpn1 to further reduce contamination of the
samples with plasmid DNA. Aliquots (5 µl out of 200 µl)
of each sample were submitted to a 30-cycle PCR analysis
using the following oligodeoxynucleotides: GFPs, 5'-
GACGACGGCAACTACAAGAC and GFPas, 5'-TCGTC-
CATGCCGAGAGTGAT. PCR products were separated on a
2% agarose-TAE gel, and revealed with ethidium bromide
staining. For real-time PCR analysis, 2 µl of each DNA
preparation were subjected to a 45-cycle PCR in 20 µl total
volume containing 10 µl of QuantiTect SYBR Green PCR
master mix (Qiagen). Amplification curves were analyzed
with Light Cycler relative quantification software v1.0,
and quantifications were determined relative to dilutions
of pTRIP-CMV-GFP.
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